Tech Company Financing Transactions
Arthrosi Therapeutics Funding Round
Arthrosi Therapeutics, operating out of San Diego, received $75 million in investment from Guangrun Health Industry and Reichstein Biotech.
Transaction Overview
Company Name
Announced On
7/12/2023
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series D
Investors
Guangrun Health Industry (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the development of AR882, a URAT1 inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9855 Towne Centre Dr 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere two years and accumulated a comprehensive and robust intellectual property portfolio.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Litain Yeh
Chief Medical Officer
Robert Keenan
Chief Operating Officer
Shunqi Yan
Browse more venture capital transactions:
Prev: 7/12/2023: Oritain venture capital transaction
Next: 7/12/2023: Eureka Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs